Watertown, United States
Excision BioTherapeutics, founded in 2015, is a pivotal player in the Biotechnology industry, specifically targeting Health Care and Health and Wellness. Based in the United States, the company is pioneering the development of CRISPR-based therapies with the compelling objective of curing viral infectious diseases.
Their strategic mission is centered around creating advanced gene editing therapeutics aimed at addressing the substantial medical needs for treatments of life-threatening viral infections. This initiative promises to transform the lives of affected individuals globally by providing safe and efficacious medications.
Excision BioTherapeutics recently secured a $6.85M grant investment as of September 29, 2022, with financial backing from the California Institute for Regenerative Medicine. This bolsters their capital for advancing their groundbreaking therapies and underscores significant interest from reputable investors within the sector.
